General Catalyst Group Management, LLC: 13F holdings
CIK 16379462026Q2
| Positions | 14 |
|---|---|
| Reported value | $188.5m |
| Filed | 2026-08-17 |
Top 10 holdings
| Security | Shares | Value | Weight |
|---|---|---|---|
| ArriVent BioPharma, Inc. | 1,494,786 | $51.9m | 27.5% |
| Parabilis Medicines, Inc. | 1,600,937 | $43.8m | 23.2% |
| CART Maplebear, Inc. | 710,711 | $33.7m | 17.9% |
| Maze Therapeutics, Inc. | 1,035,910 | $30.9m | 16.4% |
| Odyssey Therapeutics, Inc. | 810,272 | $15.2m | 8.0% |
| Eikon Therapeutics, Inc. | 305,233 | $4.0m | 2.1% |
| Fractyl Health, Inc. | 4,884,186 | $3.9m | 2.1% |
| Ethos Technologies, Inc. | 74,179 | $1.3m | 0.7% |
| CPNG Coupang Inc. | 54,677 | $949,739 | 0.5% |
| AMZN Amazon.com Inc. | 3,882 | $925,236 | 0.5% |
Get the full book
import finzdata as yf
yf.Client().manager_holdings(cik="1637946")Every position, quarter by quarter since 2013, with adds, trims and exits, on the look-back bundles.